Immunogenicity analysis of staphylococcus aureus clumping factor: A genetic variants

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1338-1340

  Brady, Rebecca A ^a   Mocca, Christopher P ^a   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CLUMPING FACTOR A; EPITOPE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIGENS, BACTERIAL; COAGULASE; GENETIC VARIATION; IMMUNODOMINANT EPITOPES; MICE, INBRED BALB C; MODELS, MOLECULAR; PROTEIN CONFORMATION; STAPHYLOCOCCUS AUREUS;

EID: 84880881461     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00275-13     Document Type: Article

References (18)

1. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Communityassociated meticillin-resistant Staphylococcus aureus. Lancet 375:1557- 1568.
2. Daum RS, Spellberg B. 2012. Progress toward a Staphylococcus aureus vaccine. Clin. Infect. Dis. 54:560-567.
3. Verkaik NJ, van Wamel WJ, van Belkum A. 2011. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 3:1063-1073.
4. Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, Karaolis DK. 2009. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 27:4867-4873.
5. Josefsson E, Higgins J, Foster TJ, Tarkowski A. 2008. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 3:e2206. doi:10.1371/journal.pone.0002206.
6. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184:1572- 1580.
7. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, Lowy FD. 2008. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J. Infect. Dis. 198:571-575.
8. Gong R, Hu C, Xu H, Guo A, Chen H, Zhang G, Shi L. 2010. Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice. Clin. Vaccine Immunol. 17: 1746-1752.
9. McDevitt D, Francois P, Vaudaux P, Foster TJ. 1995. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus. Mol. Microbiol. 16:895-907.
10. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-16947.
11. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, Mininni T, Nunez L, Carriere M, Singer C, Dilts DA, Jansen KU. 2012. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J. Infect. Dis. 205:1688-1696.
12. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG. 2012. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin. Vaccine Immunol. 19:1641-1650.
13. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM. 2003. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. 71:6864- 6870.
14. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. 2008. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun. 76:5738-5744.
15. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum. Vaccin. 7(Suppl):51-59.
16. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 10: 173. doi:10.1186/1471-2180-10-173.
17. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, Hook M, Narayana SV. 2002. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen- binding MSCRAMM, clumping factor A. EMBO J. 21:6660-6672.
18. Ganesh VK, Rivera JJ, Smeds E, Ko YP, Bowden MG, Wann ER, Gurusiddappa S, Fitzgerald JR, Hook M. 2008. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog. 4:e1000226. doi:10.1371/journal. ppat.1000226.